Outlook Therapeutics Inc
F:41ON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Outlook Therapeutics Inc
F:41ON
|
US |
|
Team17 Group PLC
F:2EC
|
UK |
|
Erste Group Bank AG
OTC:EBKDY
|
AT |
|
O
|
Owens & Minor Inc
F:6OM
|
US |
|
H
|
Healthequity Inc
F:2HE
|
US |
|
RLJ Lodging Trust
NYSE:RLJ
|
US |
|
E
|
eToro Group Ltd
NASDAQ:ETOR
|
IL |
|
P
|
PC Connection Inc
XMUN:PCC
|
US |
|
Axcelis Technologies Inc
NASDAQ:ACLS
|
US |
|
E
|
ESCO Technologies Inc
SWB:ET7
|
US |
|
U
|
Universal Technical Institute Inc
F:UTI
|
US |
|
R
|
Re/Max Holdings Inc
XBER:2RM
|
US |
|
N
|
Nhoa SA
SWB:8XE
|
FR |
|
C
|
Cohen & Steers Inc
F:FG9
|
US |
|
E
|
EQB Inc
F:V22
|
CA |
Wall St Price Targets
41ON Price Targets Summary
Outlook Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for 41ON is 8.936 EUR with a low forecast of 0.804 EUR and a high forecast of 16.726 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 41ON's stock price target?
Price Target
8.936
EUR
According to Wall Street analysts, the average 1-year price target for 41ON is 8.936 EUR with a low forecast of 0.804 EUR and a high forecast of 16.726 EUR.
What is the Revenue forecast for Outlook Therapeutics Inc?
Projected CAGR
55%
Over the last 10 years, the compound annual growth rate for Revenue has been -12%. The projected CAGR for the next 8 years is 55%.
What is the Gross Profit forecast for Outlook Therapeutics Inc?
Projected CAGR
558%
The compound annual growth rate for Gross Profit over the next 3 years is 558%.
